Filtered By:
Vaccination: Hepatitis Vaccine

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 23 results found since Jan 2013.

siRNA nanotherapeutics: a promising strategy for anti-HBV therapy
Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) and liver cirrhosis worldwide. In spite of the numerous advances in the treatment of CHB, drugs and vaccines have failed because of many factors like complexity, resistance, toxicity, and heavy cost. New RNA interference (RNAi)-based technologies have developed innovative strategies to target Achilles' heel of the several hazardous diseases involving cancer, some genetic disease, autoimmune illnesses, and viral disorders particularly hepatitis B virus (HBV) infections. Naked siRNA delivery has serious challenges including failure to cross ...
Source: IET Nanobiotechnology - June 21, 2019 Category: Nanotechnology Source Type: research

5'-triphosphate siRNA targeting HBx elicits a potent anti-HBV immune response in pAAV-HBV transfected mice.
Abstract RNA with 5'-triphosphate (3p-RNA) is recognized by RNA sensor RIG-I (retinoic acid-inducible gene I protein). Previously, we reported that small interfering RNA targeting HBx (3p-siHBx) could confer potent anti-hepatitis B virus (HBV) efficacy via HBx silencing and RIG-I activation. However, the characteristics of innate and adaptive immunity especially exhaustion profiles in the liver microenvironment in response to 3p-siHBx therapy have not been fully elucidated. Here, we observed that 3p-siHBx more significantly inhibited HBV replication in vivo. 3p-siHBx enhanced natural killer (NK) cell activation wi...
Source: Antiviral Research - November 15, 2018 Category: Virology Authors: Han Q, Hou Z, Yin C, Zhang C, Zhang J Tags: Antiviral Res Source Type: research

Silencing of the foot-and-mouth disease virus internal ribosomal entry site by targeting relatively conserved region among serotypes
AbstractFoot-and-mouth disease (FMD) is a host-restricted disease of cloven-hoofed animals, such as cattle and pigs. There are seven major serotypes of FMD virus that exhibit high antigenic variation, making vaccine strain selection difficult. However, there is an internal ribosomal entry site (IRES) element within the 5 ′ untranslated region of the FMD virus (FMDV) RNA genome that is relatively conserved among FMDV serotypes and could be used as a pan-serotype target for disease interventions. To determine the potential for targeting the IRES as promising drug target, we designed a short interfering RNA (siRNA) t argeti...
Source: Virus Genes - July 30, 2019 Category: Genetics & Stem Cells Source Type: research

SOCS and Herpesviruses, With Emphasis on Cytomegalovirus Retinitis
Christine I. Alston1,2 and Richard D. Dix1,2* 1Department of Biology, Viral Immunology Center, Georgia State University, Atlanta, GA, United States 2Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, United States Suppressor of cytokine signaling (SOCS) proteins provide selective negative feedback to prevent pathogeneses caused by overstimulation of the immune system. Of the eight known SOCS proteins, SOCS1 and SOCS3 are the best studied, and systemic deletion of either gene causes early lethality in mice. Many viruses, including herpesviruses such as herpes simplex virus and cytomega...
Source: Frontiers in Immunology - April 10, 2019 Category: Allergy & Immunology Source Type: research

Efficient replication of blood borne Hepatitis C Virus in human fetal liver stem cells
Conclusion: Our data showed that the entire bbHCV life cycle could be naturally imitated in hFLSCs. This model is expected to provide a powerful tool for exploring the process and the mechanism of bbHCV infection at the cellular level, and evaluating the treatment and preventive strategies of bbHCV infection. This article is protected by copyright. All rights reserved.
Source: Hepatology - April 13, 2017 Category: Internal Medicine Authors: Xuan Guo, Shu Wang, Zhi ‐Gang Qiu, Ya‐Ling Dou, Wei‐Li Liu, Dong Yang, Zhi‐Qiang Shen, Zhao‐Li Chen, Jing‐Feng Wang, Bin‐ Zhang, Xin‐Wei Wang, Xiang‐Fei Guo, Xue‐Lian Zhang, Min Jin, Jun‐Wen Li Tags: Viral Hepatitis Source Type: research

Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination
Publication date: June 2018Source: Current Opinion in Virology, Volume 30Author(s): Claudia Dembek, Ulrike Protzer, Michael RoggendorfThe currently used nucleoside analogs (i.e. entecavir and tenofovir) with high barrier-to-resistance efficiently suppress viral replication, limit inflammation and reduce the sequelae of chronic hepatitis B, but cannot cure the disease and thus have to be applied long-term. Therapeutic vaccination as an approach to cure chronic hepatitis B has shown promising pre-clinical results, nevertheless the proof of its efficacy in clinical trials is still missing. This may be partially due to subopti...
Source: Current Opinion in Virology - July 5, 2018 Category: Virology Source Type: research

5′-triphosphate siRNA targeting HBx elicits a potent anti-HBV immune response in pAAV-HBV transfected mice
Publication date: Available online 15 November 2018Source: Antiviral ResearchAuthor(s): Qiuju Han, Zhaohua Hou, Chunlai Yin, Cai Zhang, Jian ZhangAbstractRNA with 5′-triphosphate (3p-RNA) is recognized by RNA sensor RIG-I (retinoic acid–inducible gene I protein). Previously, we reported that small interfering RNA targeting HBx (3p-siHBx) could confer potent anti–hepatitis B virus (HBV) efficacy via HBx silencing and RIG-I activation. However, the characteristics of innate and adaptive immunity especially exhaustion profiles in the liver microenvironment in response to 3p-siHBx therapy have not been fully elucidated. ...
Source: Antiviral Therapy - November 16, 2018 Category: Virology Source Type: research

Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response
The central role of the cellular immune response in the control and clearance of the hepatitis B virus (HBV) infection has been well-established. The contribution of humoral immunity, including B cell and antibody responses against HBV, has been investigated for a long time but has attracted increasing attention again in recent years. The anti-HBs antibody was first recognized as a marker of protective immunity after the acute resolution of the HBV infection (or vaccination) and is now defined as a biomarker for the functional cure of chronic hepatitis B (CHB). In this way, therapies targeting HBV-specific B cells and the ...
Source: Frontiers in Immunology - September 23, 2019 Category: Allergy & Immunology Source Type: research

A Novel Flavivirus-based System For Production Of Hepatitis C Virus (HCV): Production Of Infectious Virions And Development Of A Novel Reporter System For Studying HCV Virion Entry.
A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV EntryDescription of Technology: HCV has infected an estimated 3% of the world population in whom viral infection persists for more than two third of the cases, often resulting in life-threatening complications. The standard of care (pegylated interferon alpha-2 plus ribavirin) is efficient in only 50% of treated patients, costly and has numerous side effects. In addition, viral resistance to newly developed drugs -- targeting viral protease or RNA polymerase -- has been described, but no vacci...
Source: NIH OTT Licensing Opportunities - June 23, 2009 Category: Research Authors: ott-admin Source Type: research

A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry
HCV has infected an estimated 3% of the world population in whom viral infection persists for more than two third of the cases, often resulting in life-threatening complications. The standard of care (pegylated interferon alpha-2 plus ribavirin) is efficient in only 50% of treated patients, costly and has numerous side effects. In addition, viral resistance to newly developed drugs -- targeting viral protease or RNA polymerase -- has been described, but no vaccine is yet available. The difficulty in developing HCV vaccines is largely due to the broad sequence-diversity displayed by HCV, the frequent occurrence of viral mut...
Source: NIH OTT Licensing Opportunities - June 23, 2009 Category: Research Authors: ott-admin Source Type: research

Viruses, Vol. 14, Pages 657: HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure
ung Despite the availability of effective vaccines and antiviral therapy over the past two to three decades, chronic hepatitis B virus (HBV) infection remains a major global health threat as a leading cause of cirrhosis and liver cancer. Functional HBV cure defined as hepatitis B surface antigen (HBsAg) loss and undetectable serum HBV DNA is associated with improved clinical outcomes in patients with chronic HBV infection. However, spontaneous loss of HBsAg is rare and occurs in only 1% of all HBsAg-positive individuals annually. Furthermore, the rate of functional cure with currently available antiviral therapy is eve...
Source: Viruses - March 22, 2022 Category: Virology Authors: Maryam Moini Scott Fung Tags: Review Source Type: research

Abstracts of Presentations at the Association of Clinical Scientists 143 < sup > rd < /sup > Meeting Louisville, KY May 11-14,2022
Conclusion: These assays are suitable for routine diagnostic. The UltraFast NextGenPCR is the fastest with average time (30mins), followed by Agilent (2 hrs) and MassArray (6hrs). Upon completion of this activity, participants should be able to examine, measure and compare results from different assays for SARS detection, evaluate and diagnose accurately, as well as being able to plan, organize and recommend a diagnostic procedure for diagnostic laboratory. Key words: SARS-CoV-2, RNA extraction, RT-PCR, limit of detection, quantification cycle, COVID-19, in vitro diagnostic tests, Agilent, Massarray, Ultrafast. [20] From t...
Source: Annals of Clinical and Laboratory Science - July 1, 2022 Category: Laboratory Medicine Source Type: research